A recent study found that oral semaglutide offers meaningful cardiovascular benefits for people with type 2 diabetes, lowering risk by 14%. Results from the Semaglutide Cardiovascular Outcomes Trial ...

In a surprising shift from its original purpose, Ozempic, a widely used weight loss drug —is now being linked to heart protection. Researchers have found that semaglutide, the drug’s active ...

Semaglutide 1 mg improves walking distance in patients with early peripheral artery disease and type 2 diabetes, regardless ...

The American College of Cardiology (ACC) gave popular obesity medications equal standing with diet and exercise as a ...

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, with many patients quitting GLP-1 treatment within a year.

As more people resort to a new generation of drugs to achieve the perfect body, Leah Hardy examines the latest warnings over ...

Novo Nordisk’s campaign, which aims to speak ‘without filters’ by declaring obesity a disease, has been strongly criticized ...

Semaglutide therapy in patients with obese heart failure leads to marked weight loss and notable gains in mood, function, and ...

Semaglutide appears to reduce the risk of death, heart attack and stroke in adults with type 2 diabetes more effectively than ...

In the context of new anti-obesity medications, the American College of Cardiology has issued a Scientific Statement updating ...

International researchers studied data from 7,899 patients treated with semaglutide and 7,899 treated with empagliflozin to look for differences in the risk of death, heart attack, stroke ...

For patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in ...